title: Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone.
abstract: BACKGROUND
  Adjuvant chemotherapy of oral uracil/ftorafur (UFT) plus leucovorin (LV) has been accepted as the standard of care in the treatment of patients with stage II and III carcinoma of the colon. The objective of the study was to compare HRQOL reported by patients receiving oral UFT plus LV (UFT/LV group) versus no adjuvant treatment (control group) following surgery for colorectal cancer.
  
  
  METHODS
  Ninety nine patients in the UFT/LV group and 83 in the control group participated. HRQOL was assessed with the European Organization for Research and Treatment of Cancer QLQ-C30 and HRQOL data measured longitudinally following surgery were compared between the groups.
  
  
  RESULTS
  Eighty-eight percent (87 of 99) received all scheduled doses of UFT plus LV during the first three cycles, and 82 percent (81 of 99) did so for five cycles. The most common type of toxicity in the UFT/LV group was fatigue, which was generally mild. Six patients each had grade 3 diarrhea or anorexia. There were significant differences in the scores for role function, and specific limitations such as fatigue, nausea, and vomiting, dyspnoea, appetite loss, and financial difficulties, which deteriorated in the UFT/LV group.
  
  
  CONCLUSIONS
  HRQOL in colorectal cancer patients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased stage of tumor between the groups. Symptom management and social support would improve HRQOL in such a group of patients.
authors.affiliation: Department of Gastroenterological and General Surgery, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan. at1151proc@med.showa-u.ac.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Tsunoda
authors.forename: Kentaro
authors.initials: K
authors.lastname: Nakao
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tsunoda
authors.forename: Makoto
authors.initials: M
authors.lastname: Watanabe
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Matsui
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000523:psychology / Q000601:surgery*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D003082:Colectomy / Q000009:adverse effects / Q000523:psychology; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000523:psychology / Q000601:surgery*; D003125:Colostomy / Q000009:adverse effects / Q000523:psychology; D004338:Drug Combinations; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011795:Surveys and Questionnaires; D005641:Tegafur / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil; D002955:Leucovorin